Combined hormonal contraceptives with folates: Benefits in the treatment of acne
Objective. To carry out a systematic analysis of the data available in the current literature on the prevalence of acne in women of different age groups, the effect of sex steroids on the pathophysiological components of acne development, the role of combined oral contraceptives (COCs) in correcting acne, and the additional therapeutic effect of folate-containing COCs.Kasyan V.N.
Material and methods. The review included the data of foreign and Russian articles published in the past 10 years and found in PubMed on this topic.
Results. The paper describes the prevalence of acne in women of different age groups, the effect of sex hormones on sebaceous glands, hair follicles, and the process of keratinization, and the role of the microflora and inflammatory processes in the genesis of acne. It shows differential diagnostic steps in the identification of acne. There are results of multicenter studies evaluating the efficacy of combined hormonal contraceptives with drospirenone for treatment of acne and data on the benefits of folate-containing COCs in patients with this condition.
Conclusion. When summarizing the literature data, it should be noted that the prescription of drospirenone-containing combined hormonal contraceptive with folates is the pathophysiological basis for the treatment of acne in reproductive-aged women. The investigation results prove that there is a significant skin improvement just after 3-month COC use in the correction of folate levels the women, by taking into account their reproductive potential.
Keywords
acne
contraception
drospirenone
metafolin
folic acid
References
1. Акне. Клинические рекомендации. 2016. Рубрикатор клинических рекомендаций Минздрава РФ. Available at: http://cr.rosminzdrav.ru/schema.html?id=721#/text [Acne. Clinical recommendations. 2016. The rubric of clinical recommendations of the Ministry of Health of the Russian Federation. Available at: http://cr.rosminzdrav.ru/schema.html?id=721#/text (in Russian)]
2. Williams H.C., Dellavalle D.P., Garner S. Acne vulgaris. Lancet. 2012; 379(9813): 361-72.
3. Dreno B. Treatment of adult female acne: a new challenge. J. Eur. Acad. Dermatol. Venereol. 2015; 29(Suppl. 5): 14-9.
4. Collier C.N., Harper J.C., Cafardi J.A., Cantrell W.C., Wang W., Foster K.W., Elewski B.E. The prevalence of acne in adults 20 years and older. J. Am. Acad. Dermatol. 2008; 58(1): 56-9.
5. Holzmann R., Shakery K. Postadolescent acne in females. Skin Pharmacol. Physiol. 2014; 27(Suppl. 1): 3-8.
6. Tan J.K., Li Y., Fung K., Gupta A.K., Thomas D.R., Sapra S. et al. Divergence of demographic factors associated with clinical severity compared to QoL impact in acne. J. Cutan. Med. Surg. 2008: 12(5): 235-42.
7. Schafer T., Niehnaus A., Vieluf D., Berger J., Ring J. Epidemiology of acne in the general population: the risk of smoking. Br. J. Dermatol. 2001;145: 100-4.
8. Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol. Ther. 2015; 28(3): 166-72.
9. Zouboulis C.C. Acne and sebaceous gland function. Clin. Dermatol. 2004; 22(5): 360-6.
10. Clarke S.B., Nelson A.M., George R.E., Thiboutot D.M. Pharmacologic modulation of sebaceous gland activity: mechanisms and clinical applications. Dermatol. Clin. 2007; 25(2): 137-46.
11. Thiboutot D. Overview of acne and its treatment. Cutis. 2008; 81(Suppl. 1): 3-7.
12. Монахов С.А., Иванов О.Л. Эстроген-гестагенные препараты в дерматологической практике. Методическое пособие для врачей. М.: «Чай Принт»; 2014. 32с. [Monakhov S.A., Ivanov O.L. Estrogen-progestin drugs in dermatological practice. A methodical manual for doctors. Moscow: “Chai Print”; 2014. 32p. (in Russian)]
13. Kim G.K., Michaels B.B. Post-adolescent acne in women: more common and more clinical considerations. J. Drugs Dermatol. 2012; 11(6):708-13.
14. Синдром поликистоза яичников. Клинические рекомендации. 2016. Рубрикатор клинических рекомендаций Минздрава РФ. Available at: http://cr.rosminzdrav.ru/schema.html?id=181#/text [Polycystic ovary syndrome. Clinical recommendations. 2016. The rubric of clinical recommendations of the Ministry of Health of the Russian Federation. Available at: http://cr.rosminzdrav.ru/schema.html?id=181#/text (in Russian)]
15. Thiboutot D., Gilliland K., Light J., Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch. Dermatol. 1999; 135(9): 1041-5.
16. Lam C., Zaenglein A.L. Contraceptive use in acne. Clin. Dermatol. 2014; 32(4): 502-15.
17. George R., Clarke S., Thiboutot D. Hormonal therapy for acne. Semin. Cutan. Med. Surg. 2008; 27(3): 188-96.
18. Albuquerque R.G., Rocha M.A., Bagatin E., Tufik S., Andersen M.L. Could adult female acne be associated with modern life? Arch. Dermatol. Res. 2014; 306(8): 683-8.
19. Bhate K., Williams H.C. What’s new in acne? An analysis of systematic reviews published in 2011–2012. Clin. Exp. Dermatol. 2014; 39(3): 273-8.
20. Thiboutot D., Gollnick H., Bettoli V., Dréno B., Kang S., Leyden J.J. et al.; Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group. J. Am. Acad. Dermatol. 2009; 60(5, Suppl.): S1-50.
21. National Institute of health and Clinical Excellence. Clinical knowledge summary: acne vulgaris. Available at: http://www.cks.nhs.uk/acne_vulgaris Accessed Sept 15, 2010.
22. Goulden V., Clark S.M., Cunliffe W.J. Post-adolescent acne: a review of clinical features. Br. J. Dermatol. 1997; 136: 66-70.
23. Ebede T.L., Arch E.L., Berson D. Hormonal treatment of acne in women. J. Clin. Aesthet. Dermatol. 2009: 2: 16-22.
24. Knaggs H.E., Wood E.J., Rizer R.L., Mills O.H. Post-adolescent acne. Int. J. Cosmet. Sci. 2004; 26(3): 129-38.
25. WHO. Medical eligibility criteria for contraceptive use. 5th ed. WHO; 2015. 276p. Available at: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf
26. Koltun W., Maloney J.M., Marr J., Kunz M. Treatment of moderate acne vulgaris unsing a combined oral contraceptive containing ethinylestradiol 20mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 155(2): 171-5.
27. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586.
28. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst. Rev. 2012; (7): CD004425. doi: 10.1002/14651858.CD004425.pub6.
29. Palli M.B., Reyes-Habito C.M., Lima X.T., Kimball A.B. A singlecenter, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. J. Drugs Dermatol. 2013; 12(6): 633-7.
30. Maloney J.M., Dietze P. Jr., Watson D., Niknian M., Lee-Rugh S., Sampson-Landers C., Korner P. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20mg ethinyl estradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J. Drugs Dermatol. 2009; 8(9): 837-44.
31. Lucky A.W., Koltun W., Thiboutot D., Niknian M., Sampson-Landers C., Korner P., Marr J. A combined oral contraceptive containing 3mg drospirenone/20mg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008; 82(2): 143-50.
32. Fenton C., Wellington K., Moen M.D., Robinson D.M. Drospirenone/ethinylestradiol 3 mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007; 67(12): 1749-65.
33. Thorneycroft I.H. Evolution of progestins. Focus on the novel progestin drospirenone. J. Reprod. Med. 2002; 47(11, Suppl.): 975-80.
34. Harper J.C. Should dermatologists prescribe hormonal contraceptives for acne? Dermatol. Ther. 2009; 22(5): 452-7.
35. Knott А., Mielke Н., Koop U., Wolber R., Burkhardt T., Vietzke J.P. et al. Folic acid: cellular uptake and penetration into human skin. J. Invest. Dermatol. 2007; 127(10): 2463-6.
36. George L., Mills J.L., Johansson A.L., Nordmark A., Olander B., Granath F., Cnattingius S. Plasma folate levels and risk of spontaneous abortion. JAMA. 2002; 288(15): 1867-73.
37. Lamers Y., Prinz-Langenohl R., Moser R., Pietrzik K. Supplementation with [6S]‑5‑methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am. J. Clin. Nutr. 2004; 79(3): 473-8.
Received 09.06.2017
Accepted 23.06.2017
About the Authors
Victoria Kasyan, MD, PhD, Associate Professor of Gynecology, Department of reproductive medicine and surgery, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia. 127473, Russia, Moscow, Delegatskaya str. 20-1. Tel.: +74959898020. E-mail: gynendo-nkc@yandex.ruFor citations: Kasyan V.N. Combined hormonal contraceptives with folates: Benefits in the treatment of acne. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (10): 130-5. (in Russian)
https://dx.doi.org/10.18565/aig.2017.10.130-135
Similar Articles
